Edition:
United Kingdom

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

123.77USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$123.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
507,915
52-wk High
$141.81
52-wk Low
$92.57

Select another date:

Thu, Apr 4 2019

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

BOSTON Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

UPDATE 3-Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe

BOSTON, April 4 Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

Alexion wins early U.S. approval for rare blood disorder drug

The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

UPDATE 2-Alexion wins early U.S. approval for rare blood disorder drug

Dec 21 The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant market position.

U.S. FDA approves Alexion Pharma's blood disorder drug

Dec 21 The U.S. Food and Drug Administration has approved Alexion Pharmaceuticals Inc's blood disorder drug Ultomiris, the pharma regulator's website showed https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108 on Friday.

Select another date: